专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US06640149B1 System and method of developing a can bottom profile and a can with a domed bottom structure 失效
标题翻译：开发罐底型材的系统和方法以及具有圆顶底部结构的罐体
公开(公告)号：US06640149B1
公开(公告)日：2003-10-28
申请号：US09532167
申请日：2000-03-21
申请人： Dubravko Nardini , Yi Gao , Stuart MacEwen
发明人： Dubravko Nardini , Yi Gao , Stuart MacEwen
IPC分类号： G06F1750
CPC分类号： B21D51/26 , G06F17/50
摘要： A method of developing a can (e.g. beverage) bottom profile is presented. More specifically, finite element analysis on a parametric representation of a beverage can is used for developing an improved beverage can design. By specifying performance parameters that the beverage can must meet and providing specific geometric limitations on the design an improved beverage can design is obtained. The resulting improved beverage can design is independent of the gauge of the material used in construction thereof. The improved beverage can provides a concave dome on the bottom of the can connected to a bottom stand which in turn is connected to a cylindrical side wall of the can via a slanted connecting wall.
摘要翻译：提出了一种开发罐（例如饮料）底部轮廓的方法。更具体地说，使用饮料罐参数表示的有限元分析来开发改进的饮料罐设计。通过指定饮料必须满足的性能参数并在设计上提供具体的几何限制，可以获得改进的饮料罐设计。所得到的改进的饮料罐设计与其在构造中使用的材料的规格无关。改进的饮料可以在连接到底架上的罐的底部上提供凹入的圆顶，底座又通过倾斜的连接壁连接到罐的圆柱形侧壁。

43. 发明授权

US08686026B2 Solid compositions 有权
标题翻译：固体成分
公开(公告)号：US08686026B2
公开(公告)日：2014-04-01
申请号：US13156783
申请日：2011-06-09
申请人： Bernd Liepold , Tina Jung , Peter Hölig , Rudolf Schroeder , Nancy E. Sever , Justin S. Lafountaine , Brent D. Sinclair , Yi Gao , Jianwei Wu
发明人： Bernd Liepold , Tina Jung , Peter Hölig , Rudolf Schroeder , Nancy E. Sever , Justin S. Lafountaine , Brent D. Sinclair , Yi Gao , Jianwei Wu
IPC分类号： A61K31/401
CPC分类号： A61K31/4025 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/1694 , A61K9/2027 , A61K9/2054 , A61K31/00
摘要： The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
摘要翻译：本发明的特征在于包含无定形化合物I的固体组合物。例如，化合物I可以配制成包含药学上可接受的亲水性聚合物，优选药学上可接受的表面活性剂的无定形固体分散体。

44. 发明授权

US08557995B2 Solid dispersions containing kinase inhibitors 失效
标题翻译：含有激酶抑制剂的固体分散体
公开(公告)号：US08557995B2
公开(公告)日：2013-10-15
申请号：US13154562
申请日：2011-06-07
申请人： Jonathan M. Miller , Rajeev Gokhale , Eric A. Schmitt , Yi Gao , Justin Lafountaine , Lloyd Dias
发明人： Jonathan M. Miller , Rajeev Gokhale , Eric A. Schmitt , Yi Gao , Justin Lafountaine , Lloyd Dias
IPC分类号： A61K31/44 , C07D513/02
CPC分类号： A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2077 , A61K31/4743
摘要： A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.
摘要翻译：固体分散体以基本上非结晶的形式包含激酶抑制化合物，例如N-（4- {4-氨基-7- [1-（2-羟乙基）-1H-吡唑-4-基]噻吩并[ 3,2-c]吡啶-3-基}苯基）-N' - （3-氟苯基）脲，分散在固体基质中，其包含（a）药学上可接受的水溶性聚合物载体和（b）药学上可接受的表面活性剂。制备这种固体分散体的方法包括将化合物，聚合物载体和表面活性剂溶解在合适的溶剂中，并除去溶剂以提供包含聚合物载体和表面活性剂的固体基质，并使化合物分散在基本上不结晶形成。固体分散体适合于有需要的受试者口服给药以治疗癌症。

45. 发明授权

US08178548B2 Anti-infective agents and uses thereof 有权
公开(公告)号：US08178548B2
公开(公告)日：2012-05-15
申请号：US12212315
申请日：2008-09-17
申请人： Pamela L. Donner , John T. Randolph , Allan C. Krueger , David A. Betebenner , Douglas K. Hutchinson , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , John K. Pratt , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , John E. Hengeveld , Rodger F. Henry , Xiaochun Lou , Geoff G. Z. Zhang
发明人： Pamela L. Donner , John T. Randolph , Allan C. Krueger , David A. Betebenner , Douglas K. Hutchinson , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , John K. Pratt , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , John E. Hengeveld , Rodger F. Henry , Xiaochun Lou , Geoff G. Z. Zhang
IPC分类号： A61K31/505 , C07D239/02 , C07D401/00
CPC分类号： C07D239/22 , A61K31/513 , C07D239/54 , C07D239/553 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10
摘要： This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

46. 发明申请

US20090263477A1 SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF 审中-公开
标题翻译：非洲酸及其制药制剂的销售
公开(公告)号：US20090263477A1
公开(公告)日：2009-10-22
申请号：US12490174
申请日：2009-06-23
申请人： Russell D. Cink , Joseph B. Paterson , Yi Gao , Geoff G. Z. Zhang , Michelle A. Long , John B. Morris , Joerg Rosenberg
发明人： Russell D. Cink , Joseph B. Paterson , Yi Gao , Geoff G. Z. Zhang , Michelle A. Long , John B. Morris , Joerg Rosenberg
IPC分类号： A61K9/48 , A61K31/366 , A61K9/00 , A61P9/00
CPC分类号： C07C65/40 , A61K9/146 , C07C51/412 , C07C59/88 , C07C215/08 , C07C215/12 , C07D295/037
摘要： In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients.In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
摘要翻译：在一个方面，本发明涉及分子分散体形式的制剂，其包括i）非诺贝酸，其生理学上可接受的盐或其衍生物和任选的其它活性物质，ii）包含至少一种肠溶粘合剂的粘合剂组分， iii）其他生理上可接受的赋形剂。在第二方面，本发明涉及当与非诺贝酸的其它盐相比时，可光稳定的非诺贝酸的新型盐。

47. 发明申请

US20090186912A1 ANTI-INFECTIVE AGENTS AND USES THEREOF 有权
公开(公告)号：US20090186912A1
公开(公告)日：2009-07-23
申请号：US12212323
申请日：2008-09-17
申请人： Charles A. Flengte , Douglas K. Hutchinson , David A. Betebenner , David A. DeGoey , Pamela L. Donner , Warren M. Kati , Allan C. Krueger , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , Christopher E. Motter , John K. Pratt , John T. Randolph , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , Xiaochun Lou , Geoff G.Z. Zhang
发明人： Charles A. Flengte , Douglas K. Hutchinson , David A. Betebenner , David A. DeGoey , Pamela L. Donner , Warren M. Kati , Allan C. Krueger , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , Christopher E. Motter , John K. Pratt , John T. Randolph , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , Xiaochun Lou , Geoff G.Z. Zhang
IPC分类号： A61K31/513 , C07D239/10 , C07D401/10 , A61K31/506 , A61P31/12
CPC分类号： C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
摘要： This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

48. 发明申请

US20090176784A1 ANTI-INFECTIVE AGENTS AND USES THEREOF 有权
标题翻译：抗感染药物及其用途
公开(公告)号：US20090176784A1
公开(公告)日：2009-07-09
申请号：US12212315
申请日：2008-09-17
申请人： Pamela L. Donner , John T. Randolph , Allan C. Krueger , David A. Betebenner , Douglas K. Hutchinson , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , John K. Pratt , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , John E. Hengeveld , Rodger F. Henry , Xiaochun Lou , Geoff G.Z. Zhang
发明人： Pamela L. Donner , John T. Randolph , Allan C. Krueger , David A. Betebenner , Douglas K. Hutchinson , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , John K. Pratt , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , John E. Hengeveld , Rodger F. Henry , Xiaochun Lou , Geoff G.Z. Zhang
IPC分类号： A61K31/5377 , C07D239/22 , A61K31/513 , C07D401/10 , C07D413/10 , C12N7/06
CPC分类号： C07D239/22 , A61K31/513 , C07D239/54 , C07D239/553 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10
摘要： This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
摘要翻译：本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式